A recent study warns that Metabolic dysfunction-associated steatotic liver disease is on track to affect 1.8 billion people globally by 2050. Researchers attribute this alarming rise primarily to increasing obesity rates and high blood sugar levels worldwide.
A Rapidly Growing Global Health Burden
Previously known as Non-alcoholic fatty liver disease, MASLD has emerged as one of the most prevalent and fastest-growing liver conditions. According to findings from the Global Burden of Disease Study, approximately 1.3 billion people are currently living with the disease—marking a staggering 143% increase over the past three decades. In fact, nearly one in six individuals globally is affected.
Rising Numbers Driven by Lifestyle Changes
Over time, the number of MASLD cases has increased dramatically. In 1990, around 500 million people were affected; by 2023, this figure rose to 1.3 billion. Looking ahead, projections indicate a further 42% increase by 2050. This surge is largely driven by population growth combined with lifestyle changes, particularly rising obesity and poor glycaemic control.
Increasing Prevalence Across Demographics
As reported by The Guardian, the global prevalence rate reached 14,429 cases per 100,000 people in 2023, reflecting a 29% increase since 1990. Although MASLD is more common in men and shows the highest prevalence among older adults aged 80–84, a significant number of cases occur in younger populations. Notably, the disease affects men aged 35–39 and women aged 55–59 in large numbers.
Key Risk Factors and Regional Trends
Importantly, high blood sugar remains the leading contributor to MASLD-related health complications. This is followed by high body mass index and smoking, underscoring strong links with Type 2 diabetes and obesity.
Geographically, regions such as North Africa and the Middle East report disproportionately higher prevalence rates. Meanwhile, countries worldwide continue to see sharp increases. For instance, prevalence rose by 33% in the UK, 30% in Australia, and 22% in the United States between 1990 and 2023.
Improved Care but Rising Case Load
Encouragingly, despite the growing number of cases, the overall disease burden—measured in years lost due to illness or premature death—has remained relatively stable. This suggests that advances in medical care and early-stage detection are helping patients live longer and healthier lives.
However, the rising number of cases still poses a major concern. Many individuals remain at risk of progressing to severe complications such as liver cirrhosis or cancer in the future.
Silent Nature and Clinical Presentation
MASLD often develops silently, with many individuals remaining unaware of the condition. Typically, it is detected incidentally during routine investigations. When symptoms do occur, they may include fatigue, general malaise, and discomfort or pain in the upper right abdomen.
Call for Global Action
The study, led by the Institute for Health Metrics and Evaluation at the University of Washington, highlights a worrying trend: MASLD is increasingly affecting younger adults due to worsening lifestyle patterns.
Therefore, the authors emphasize the urgent need to recognize MASLD as a global health priority. They call for stronger public health policies, targeted awareness campaigns, and early interventions to curb its rising impact and prevent long-term complications.